0
Back To Top Jump Location
Sign In  | Cart
Left Shadow
Right Shadow
Clinical Research |

Inappropriate Implantable Cardioverter-Defibrillator Shocks in MADIT II: Frequency, Mechanisms, Predictors, and Survival Impact FREE

James P. Daubert, MD; Wojciech Zareba, MD, PhD; David S. Cannom, MD; Scott McNitt, MS; Spencer Z. Rosero, MD; Paul Wang, MD; Claudio Schuger, MD; Jonathan S. Steinberg, MD; Steven L. Higgins, MD; David J. Wilber, MD; Helmut Klein, MD; Mark L. Andrews, BBA; W. Jackson Hall, PhD; Arthur J. Moss, MD;
[+] Author Information

Supported by a research grant from Guidant Corporation, St. Paul, Minnesota, to The University of Rochester Medical Center.Reprint requests and correspondence: Dr. James P. Daubert, Box 679-URMC, Rochester, New York 14642.

American College of Cardiology Foundation

J Am Coll Cardiol. 2008;51(14):1357-1365. doi:10.1016/j.jacc.2007.09.073
Published online

Objectives  This study sought to identify the incidence and outcome related to inappropriate implantable cardioverter-defibrillator (ICD) shocks, that is, those for nonventricular arrhythmias.

Background  The MADIT (Multicenter Automatic Defibrillator Implantation Trial) II showed that prophylactic ICD implantation improves survival in post-myocardial infarction patients with reduced ejection fraction. Inappropriate ICD shocks are common adverse consequences that may impair quality of life.

Methods  Stored ICD electrograms from all shock episodes were adjudicated centrally. An inappropriate shock episode was defined as an episode during which 1 or more inappropriate shocks occurred; another inappropriate ICD episode occurring within 5 min was not counted. Programmed parameters for patients with and without inappropriate shocks were compared.

Results  One or more inappropriate shocks occurred in 83 (11.5%) of the 719 MADIT II ICD patients. Inappropriate shock episodes constituted 184 of the 590 total shock episodes (31.2%). Smoking, prior atrial fibrillation, diastolic hypertension, and antecedent appropriate shock predicted inappropriate shock occurrence. Atrial fibrillation was the most common trigger for inappropriate shock (44%), followed by supraventricular tachycardia (36%), and then abnormal sensing (20%). The stability detection algorithm was programmed less frequently in patients receiving inappropriate shocks (17% vs. 36%, p = 0.030), whereas other programming parameters did not differ significantly from those without inappropriate shocks. Importantly, patients with inappropriate shocks had a greater likelihood of all-cause mortality in follow-up (hazard ratio 2.29, p = 0.025).

Conclusions  Inappropriate ICD shocks occurred commonly in the MADIT II study, and were associated with increased risk of all-cause mortality.

Figures in this Article
AF

atrial fibrillation or atrial flutter

ATP

antitachycardia pacing

CHF

congestive heart failure

HR

hazard ratio

ICD

implantable cardioverter-defibrillator

SVT

supraventricular tachycardia

VF

ventricular fibrillation

VT

ventricular tachycardia

Implantable cardioverter-defibrillator (ICD) therapy is proven to reduce mortality (15). However, inappropriate shocks for atrial arrhythmias with rapid ventricular conduction (67) or for abnormal sensing (810) results in multiple adverse effects (1114) including impaired quality of life (15), psychiatric disturbances (16), and even provocation of nonfatal (17) or fatal (18) ventricular arrhythmia. Although inappropriate shocks have been studied in some ICD groups (1920), no reports have detailed inappropriate ICD therapy in a pure primary prevention group like those in the MADIT II study.

ICD devices and programming

The MADIT II protocol permitted implantation of U.S. Food and Drug Administration–approved single-chamber or dual-chamber Guidant ICDs. Each ICD stored intracardiac electrograms for arrhythmia episodes. Moreover, each unit offered 2 algorithms intended to minimize inappropriate shocks: 1) “stability,” evaluating the regularity of the tachyarrhythmia; and 2) “sudden onset,” the degree to which the arrhythmia began suddenly versus gradually (21). The dual-chamber devices provided additional algorithms evaluating the atrial rate (22). The ICD programming, including such discriminator usage, was left to the discretion of the investigators using standard clinical practice.

ICD therapy event analysis

The MADIT II study randomly allocated 742 patients to the ICD arm, but 1 withdrew consent and 22 never received an ICD, leaving 719 that could be evaluated for inappropriate shocks. The ICDs were interrogated quarterly and after ICD shocks. The ICD therapy was defined as either antitachycardia pacing (ATP) or ICD shock. Two investigators (J.P.D, W.Z.) categorized the rhythm prompting ATP or shock using the stored electrograms. Any ICD therapy not delivered for VT or VF was deemed inappropriate, and the rhythm triggering therapy categorized as: atrial fibrillation or atrial flutter (AF), supraventricular including sinus tachycardia (SVT), or inappropriate sensing using published criteria (9,19). A small percentage of rhythms triggering ICD therapy (2.2%) were unclassified because of missing or incomplete data. An episode’s termination was defined by the ICD re-detecting sinus rhythm and thus could include more than 1 shock (and/or ATP bursts). As done previously in the AVID (Antiarrhythmics Versus Implantable Defibrillators) study, a subsequent episode beginning <5 min after episode termination was ignored for this analysis (19). Thus, an inappropriate shock episode was defined as an episode during which one or more inappropriate shocks occurred; a separate ICD episode of the same type (inappropriate or appropriate) occurring <5 min later was not counted.

Statistical analysis

Clinical characteristics were compared using the Wilcoxon rank sum test for continuous variables. The chi-square test was used for dichotomous variables, except the Fisher exact test was used when 25% or more of the cells had expected cell counts fewer than 5 (sudden and nonsudden cardiac death). The Kaplan-Meier life-table method was used to graphically display the time to first event and calculate the cumulative event rates for each group and within each group by risk factors. The results were compared using the log-rank statistic.

Using printouts or ICD discs downloaded after an inappropriate shock prompted interrogation, the major tachyarrhythmia detection settings were compared for the 83 inappropriate shock patients to 83 randomly chosen subjects without inappropriate shock. The latter group was matched with the inappropriate shock group for the presence or absence of 3 variables associated with inappropriate shock, prior atrial fibrillation, smoking, and appropriate shock. Theoretically 8 combinations of these 3 variables existed. In reality, only 7 combinations of these 3 variables contained patients who had received an inappropriate shock. Next, from the pool of patients who did not receive an inappropriate shock, we randomly chose the same number of patients from each of the 7 groups defined by having the same combination of these 3 characteristics. A stratified difference-between-proportions test, with strata weights inversely proportional to variances, was used to derive p values for the binary variables. The Mann-Whitney rank statistic, likewise stratified, was used for the numerical variables. Unstratified versions were also carried out to evaluate consistency of findings.

Using the 83 patients who did experience an inappropriate shock and the 636 patients who did not experience inappropriate shocks, Cox proportional hazards regression models were developed to determine what factors predicted time to inappropriate shock. Similarly, again using the patients with and without inappropriate shock, Cox proportional hazards regression models were developed to determine whether the occurrence of inappropriate shocks predicted time to all-cause mortality. Variables from the clinical characteristics table that met the criteria of p value <0.20 were considered as candidates for the regression model of inappropriate shock. For the inappropriate shock end point, appropriate shock was modeled as a time-dependent covariate.

Both appropriate and inappropriate shock were modeled as time-dependent covariates in the all-cause mortality model. Additional commonly used risk factors were included in this model. Follow-up time began at ICD implantation. Unclassified rhythms (n = 13, 2.2% of total shocks) were not included in this analysis.

The statistical software used for the analyses was SAS version 9.13 (SAS Institute Inc., Cary, North Carolina). A 2-sided probability value of <0.05 identified statistical significance.

Incidence and type of inappropriate shocks—or ATP

One or more inappropriate ICD shocks occurred in 83 of 719 patients (11.5%). After 2 years of follow-up, patients had a 13% likelihood of having experienced one or more inappropriate shocks (Figure 1).(Table 1) shows patient experience with inappropriate and appropriate shocks. Thirty-two patients had more than 1 inappropriate shock episode (Table 1), ranging up to a maximum of 16 inappropriate shock episodes during 18 months of follow-up for 1 patient. Patients experiencing an inappropriate shock had a mean number of 2.2 ± 2.5 inappropriate shock episodes.

Grahic Jump Location
Figure 1

Survival Free of Inappropriate Shock/Therapy

(A) The cumulative proportion of patients who experienced a first inappropriate shock (due to any mechanism) is plotted versus time. (B) The cumulative proportion of patients who experienced a first inappropriate therapy, antitachycardia pacing (ATP) or shock (due to any mechanism) is plotted versus time. The number of patients at risk at a given time point of follow-up is indicated below the x axis. The proportion of the population experiencing the event in question is given in parentheses at the 1-, 2-, and 3-year time points.

Table Grahic Jump Location
Table 1Patients Experiencing Inappropriate ICD Shocks

(Table 2) delineates the inappropriate shocks by episode rather than by patient and shows the subclassification of inappropriate shock by mechanism. As noted above, shock episodes were counted and multiple shocks within an episode were not tallied, nor were episodes caused by the same mechanism beginning within 5 min of a prior episode (19). (Table 2) thus reflects separate ICD shock episodes rather than the total number of shocks. Atrial fibrillation or atrial flutter was the most common mechanism for inappropriate shock, followed by SVT, with inappropriate sensing the least common mechanism for inappropriate shock in the MADIT II study. The time-dependent occurrence of a patient’s first inappropriate shock caused by any of the 3 mechanisms is shown in (Figure 2), illustrating that the time course of the occurrence of the 3 types of inappropriate shocks is similar. In the cohort of 719 patients with ICDs included in this analysis, 79 (11.0%) of patients had one type of inappropriate shock, 3 (0.4%) had 2 types of inappropriate shock mechanism, and 1 (0.1%) of the patients experienced ICD shock for all 3 types of inappropriate therapy mechanism.

Table Grahic Jump Location
Table 2Rhythm Responsible for ICD Shock Episodes
Grahic Jump Location
Figure 2

Time-Dependent Occurrence of Inappropriate Shock by Type

The cumulative proportion of patients experiencing a first inappropriate (Inapp.) shock due to the 3 subcategories of inappropriate shock is plotted with respect to time. The number of patients at risk at a given time point of follow-up is indicated below the x axis. The proportion of the population experiencing the event in question is given in parentheses at the 1-, 2-, and 3-year time points. AF = atrial fibrillation or atrial flutter; ICD = implantable cardioverter-defibrillator; SVT = supraventricular tachycardia.

We analyzed the heart rate at the time of a patient’s first inappropriate shock for either AF or SVT. Inappropriate sensing episodes were excluded from this analysis only, because the true ventricular rate was actually normal for these, and not what the device reported. The mean ventricular rate triggering inappropriate shock for AF or SVT was 174 ± 22 beats/min (Figure 3). The number of patients experiencing inappropriate shock at a given rate is shown on the y axis. For instance, 3 patients had a (first) inappropriate shock for atrial fibrillation with a heart rate of 200 beats/min, and 1 patient had a heart rate of 200 beats/min because of SVT prompting inappropriate shock. At the time of inappropriate shock, the ventricular rate exceeded 160 beats/min in 78% of episodes.

Grahic Jump Location
Figure 3

Ventricular Rate Precipitating Inappropriate Shock

The heart rate at the time of the ICD detection resulting in a patient’s first inappropriate shock is shown in the bar graph in groups of 10 beats/min. Atrial fibrillation episodes are shown with cross-hatched bars, and SVT episodes are shown with solid bars. Inappropriate shocks caused by abnormal sensing are excluded because the device has by definition misconstrued the actual ventricular rate (typically normal in these cases). The events relate to shocks, not patients, in this figure. Abbreviations as in (Figure 2).

Considering any inappropriate therapy, that is inappropriate shock or ATP, this occurred in 100 of 719 (13.9%) patients (Figure 1B), of whom 17 patients experienced inappropriate ATP therapy without having at least 1 inappropriate shock during follow-up.

Clinical characteristics of patients receiving inappropriate ICD shocks

Inappropriate shock recipients differed statistically from nonrecipients (Table 3) for 3 baseline clinical characteristics: 1) prior atrial fibrillation (18.1% vs. 7.4%, p = 0.001), 2) smoking history (89.2% vs. 78.4%, p = 0.022), and 3) diastolic blood pressure ≥80 mm Hg (37.3% vs. 26.3%, p = 0.033). Considering interim events, appropriate therapy occurred more commonly in the inappropriate shock group than in those without inappropriate shocks (42.2% vs. 21.1%, p < 0.001). Notably, the proportion of patients receiving a dual-chamber ICD in the inappropriate shock group versus those without inappropriate shock was not appreciably different (Table 3), suggesting that dual-chamber ICD systems were not less prone to inappropriate shocks in MADIT II.

Table Grahic Jump Location
Table 3Clinical Characteristics of Patients With Versus Without Inappropriate ICD Shock
Table Footer NoteA dual-chamber or single-chamber device was implanted at the investigator’s discretion.
Table Footer NoteA blinded committee adjudicated deaths using a modified Hinkle-Thaler classification.

Cox proportional hazards analysis found the baseline characteristics of prior atrial fibrillation (hazard ratio [HR] 2.90, p < 0.01), smoking history (HR 2.18, p = 0.03), and diastolic blood pressure ≥80 (HR 1.61, p = 0.04) independently predicted the occurrence of inappropriate shock (Table 4). Considering time-dependent factors, prior interim appropriate shock predicted the occurrence of an inappropriate shock (HR 2.25, p = 0.03), as did interim atrial fibrillation (HR 3.45, 95% confidence interval 1.55 to 7.69, p < 0.01).

Table Grahic Jump Location
Table 4Predictors of Inappropriate Shock by Cox Proportional Hazards Regression Analysis
Programmed parameters in patients with inappropriate shocks

The SVT–VT discriminator stability function had been activated less frequently in inappropriate shock recipients (17%) than in those not receiving inappropriate shocks (36%, p = 0.030). Among dual-chamber devices, a trend toward the V>A criterion being used less frequently was seen in patients with inappropriate shocks (31% vs. 50%, p = 0.054). We did not observe other significant differences in these parameters, such as the lowest zone detection rate (Table 5).

Table Grahic Jump Location
Table 5ICD Programming in Patients With and Without Inappropriate ICD Shocks
Table Footer Notep values from stratified Mann-Whitney rank test and difference-between-proportions test, for continuous and dichotomized measures, respectively. Values were consistent with corresponding ones from nonstratified tests.
Table Footer NoteSelected randomly from among the 635 patients without inappropriate shocks, matching on history of atrial fibrillation, smoking, and appropriate shock; see text for details.
Impact of inappropriate shocks on outcomes

Inappropriate shock recipients tended to have a higher percent total mortality than those patients not experiencing inappropriate shocks (16.9% vs. 12.9%, p = 0.317, Table 3). Because appropriate shock occurrence was one predictor of inappropriate shocks (Table 4), Cox proportional hazards regression analysis was used to evaluate the independent survival impact of inappropriate ICD shocks (Table 6). In multivariate analysis, mortality was predicted by blood urea nitrogen >25 (HR 2.07, p < 0.01), absence of beta-blocker therapy (HR 1.64, p = 0.02), and interim congestive heart failure (CHF) hospitalization (HR 4.23, p < 0.01) Because inappropriate and appropriate shocks were intertwined in their occurrence, we examined them independently and together (Table 6). The occurrence of both inappropriate and appropriate shock was associated with an over 4-fold increase in probability of mortality for a given follow-up period (HR 4.08, p < 0.01). The occurrence of an inappropriate shock was associated with an HR for mortality of 2.29 (p = 0.02). Prior appropriate shock alone portended an HR of 3.36 for mortality (p < 0.01). On the other hand, neither appropriate nor inappropriate ATP was associated with a significant mortality increase (Table 6). Inappropriate shocks were not a predictor of subsequent CHF hospitalization (data not shown), although appropriate shocks were identified as a predictor of CHF events as previously reported (23).

Table Grahic Jump Location
Table 6Predictors of All-Cause Mortality by Cox Proportional Hazards Regression Analysis
Inappropriate shock epidemiology

In the MADIT II study, inappropriate ICD shocks were common, occurring in 11.5% of patients and with a cumulative 1- and 2-year event rate of 10% and 13%, respectively (Figure 1A). Overall, 184 inappropriate shock episodes occurred compared with a total of 393 appropriate shock episodes. An AF caused 44.0% of inappropriate shock episodes; SVT and inappropriate sensing were less common.

Frequent inappropriate ICD shocks and ATP occurred in other series (7,1920), such as the AVID study with 20% of patients experiencing an inappropriate shock or ATP in follow-up and 9% by 2 years of follow-up (19). Enrolling patients with prior sustained VT or VF, a higher proportion of patients experienced appropriate therapy, so the overall percent of events that were inappropriate was lower in the AVID study. Swerdlow et al. (24) had previously predicted that the proportion of inappropriate shocks of the total shock count would be higher in primary prevention ICD patients because of a lower appropriate shock rate. Enrolling a diverse ICD population, the Pain Free Study found that 15% of patients experienced inappropriate therapy (20), with the proportion of all events being inappropriate trending higher in the primary prevention subset than in the secondary prevention group (46% vs. 34%, p = 0.09) (20). In the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) study, 32% of primary prevention biventricular ICD patients had inappropriate detections, although not all of these led to shocks, and unlike in the MADIT II study and most studies, inappropriate detections for sinus tachycardia exceeded atrial arrhythmias (1920,2526).

Inappropriate shocks: root causes

Inappropriate shock patients more commonly had a history of atrial fibrillation, smoking, and/or diastolic hypertension and were more likely to also have had a prior appropriate ICD shock (Table 3). Alter et al. (27) reported that young age and nonischemic cardiomyopathy predicted inappropriate shocks. Other investigators have found that prior history of atrial fibrillation and appropriate therapy were predictors of inappropriate shocks, similar to our findings (26). Because AF was the most common inappropriate shock mechanism, its association as a predictive factor is expected. Smoking was recently found to increase the incidence of both appropriate and inappropriate shocks in the MADIT II study, possibly because of a myriad of adverse consequences such as sympathetic stimulation, increased platelet reactivity, vasoconstriction, endothelial dysfunction, and tachycardia (28). Hypertension is a potent risk factor for AF and may act in this way to promote the likelihood of an inappropriate shock. The link between appropriate and inappropriate therapy likely stems from a combination of several factors: 1) ventricular arrhythmia or its treatment (ATP or shock) provoking atrial fibrillation (2930); 2) inappropriate therapy causing VT, that is, proarrhythmia (18,27); 3) a common factor or factors predisposing to both VT/VF and AF or SVT; or 4) incorrect categorization of some appropriate episodes in a given patient as inappropriate or vice versa.

Outcomes of patients experiencing inappropriate shocks

The prior occurrence of an inappropriate shock was associated with a doubled risk of total mortality in this study even after accounting for the known association between appropriate shock and increased mortality (23) (Table 6). Possible explanations for the increased mortality in the cohort with inappropriate shocks include: 1) potential direct mechanical, arrhythmic, or hemodynamic adverse effect of the shocks themselves, such as fatal proarrhythmia (18,27) or other effects (11); and 2) baseline characteristics or interim events, such as AF, causing both inappropriate shocks and an increased risk of mortality. Because shocks bore a greater association with mortality than ATP (Table 6), explanation one may be favored. However, an alternative inference is that a more recalcitrant, persistent, rapid, or recurrent arrhythmia may have led to a shock, whereas a brief flurry of the arrhythmia may have led to ATP and not required a shock.

Implications for minimizing inappropriate therapy

We found a statistically different, lower utilization rate of the stability SVT–VT discriminator in patients with inappropriate shocks compared with patients not having inappropriate shocks, raising the possibility that more aggressive use of the available SVT discriminators could reduce the incidence of inappropriate detection. Stability was used in a minority of the overall population (Table 5), likely reflecting standard clinical practice at the time of this study. The SVT–VT discriminator usage carries the theoretical risk of underdetection of true ventricular arrhythmias, although current data suggest that underdetection due to stability usage is infrequent (9,21,3132). Nevertheless, the stability discriminator’s effectiveness in preventing therapy for atrial fibrillation is markedly reduced at rates above 170 beats/min (9). In fact, (Figure 3) shows that most of the rapidly conducted atrial fibrillation episodes causing inappropriate shocks were indeed 170 beats/min or faster. Thus, even if this discriminator had been uniformly programmed, it may not have had a major impact. Other parameters were not statistically different in the 2 groups, further arguing against programming aberrations explaining the inappropriate shocks (Table 5). Although programming a higher detection rate likely reduces the detection of atrial arrhythmias and misinterpretation of them as ventricular arrhythmias, it is clear that programming too high a rate cutoff could lead to underdetection of relatively slow monomorphic VTs or underdetection of polymorphic ventricular arrhythmias or ventricular fibrillation due to intermittent undersensing (31,3334). Although there is an incidence of sudden death in any ICD population, the extent to which this could have been prevented by the ICD or whether some of these sudden deaths are caused by underdetection of ventricular arrhythmias remains unknown.

Dual-chamber ICD systems were used approximately as commonly in patients who experienced an inappropriate shock (38.6%) as in those who did not (44.4%, Table 3). Prior studies have often failed to show a benefit of dual-chamber devices in preventing inappropriate detections of supraventricular arrhythmias (22,26,3536). The Detect Supraventricular Tachycardia Study (DETECT SVT) recently showed a reduction in the percent of total SVT episodes that were inappropriately classified as VT in the dual-chamber detection group (30.9%) than the single-chamber group (39.5%) (37). However, this means that almost one-third of the SVT episodes were still misclassified despite the dual-chamber criteria, and furthermore that total inappropriate shocks were not reduced in the dual-chamber arm (3738). Future enhancements of SVT–VT discrimination systems may yield improvements (9,33,3842).

The role of medications in preventing inappropriate shocks is mixed, with a prior study failing to find beta-blocker therapy protective from inappropriate shocks in the MADIT II study (43). However, sotalol and amiodarone have reduced inappropriate shocks by as much as 78% in a secondary prevention population (27,4445). Recently introduced continuous wireless ICD monitoring (4647) could reduce inappropriate therapies.

Study limitations

Total shocks were not counted, but rather ICD episodes containing one or more shocks were tallied. The potential additional prognostic importance of the total number of shocks cannot be evaluated. The ICD programming was not protocol specified, and although the VT cutoff rate was collected prospectively, the other parameters analyzed (Table 5) were obtained retrospectively, and the difference in stability programming must be interpreted cautiously. Moreover, parameter changes and possible effects on inappropriate shocks could not be analyzed in a time-dependent fashion. Electrogram interpretation to adjudicate appropriate versus inappropriate shocks was based on available data, which differs for single-chamber and dual-chamber systems (48). Furthermore, errors in classification may occur (49). This MADIT II substudy’s findings may not pertain to other ICD populations. Lastly, although quality of life data were collected in MADIT II and initial analysis has been performed (50), the association of inappropriate shocks and quality of life is not yet available.

Inappropriate shocks were common in the MADIT II study, as in other recently reported trials, occurring in 83 (11.5%) of the 719 MADIT II ICD patients and constituting 31.2% of all shock episodes. Smoking, atrial fibrillation, diastolic hypertension, and prior appropriate shocks were associated with an increased chance of inappropriate shock. Inappropriate shock occurrence was associated with increased probability of mortality in follow-up. Coupled with potential effects on quality of life, this association with increased mortality heightens the importance of efforts to reduce the occurrence of inappropriate shocks.

The investigators acknowledge the invaluable assistance of Ms. Jodie Palma in the review of inappropriate shock electrograms and device programming and of Mr. Thomas Ross in preparation of the manuscript.

The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias. N Engl J Med. 337 1997:1576-1583.
CrossRef | PubMed
Buxton  A., Lee  K., Fisher  J.; A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 341 1999:1882-1890.
CrossRef | PubMed
Moss  A.J., Zareba  W., Hall  W.J.; Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 348 2002:877-883.
CrossRef
Bardy  G.H., Lee  K.L., Mark  D.B.;Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 352 2005:225-237.
CrossRef | PubMed
Kadish  A., Dyer  A., Daubert  J.P.;Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 350 2004:2151-2158.
CrossRef | PubMed
Grimm  W., Flores  B.T., Marchlinski  F.E.; Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation. 87 1993:1880-1888.
CrossRef | PubMed
Rosenqvist  M., Beyer  T., Block  M.; Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. Circulation. 98 1998:663-670.
CrossRef | PubMed
Kron  J.; Clinical significance of device-related complications in clinical trials and implications for future trials: insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Card Electrophysiol Rev Cardiovasc Med. 7 2003:473-478.
CrossRef
Swerdlow  C.D., Friedman  P.A.; Advanced ICD troubleshooting: part I. Pacing Clin Electrophysiol. 28 2005:1322-1346.
CrossRef | PubMed
Gold  M.R., Peters  R.W., Johnson  J.W.; Complications associated with pectoral implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 20 1997:208-211.
CrossRef | PubMed
Epstein  A.E., Kay  G.N., Plumb  V.J.; Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation. 98 1998:1517-1524.
CrossRef | PubMed
Avitall  B., Port  S., Gal  R.; Automatic implantable cardioverter/defibrillator discharges and acute myocardial injury. Circulation. 81 1990:1482-1487.
CrossRef | PubMed
Finkelmeier  B., Kenwood  N., Summers  C.; Psychological ramifications of surviving sudden cardiac death. Crit Care Q. 1 1984:71-79.
Luderitz  B., Jung  W., Deister  A.; Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol. 16 1993:1815-1821.
CrossRef | PubMed
Schron  E.B., Exner  D.V., Yao  Q.; Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial. Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 105 2002:589-594.
CrossRef | PubMed
Prudente  L.A.; Phantom shock in a patient with an implantable cardioverter defibrillator: case report. Am J Crit Care. 12 2003:144-146.
PubMed
Jones  G., Johnson  G., Troutman  C.; Incidence of atrial fibrillation following ventricular defibrillation with transvenous lead systems in man. J Cardiovasc Electrophysiol. 3 1992:411-417.
CrossRef
Vollmann  D., Luthje  L., Vonhof  S.; Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2 2005:307-309.
CrossRef | PubMed
Klein  R.C., Raitt  M.H., Wilkoff  B.L.; Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Cardiovasc Electrophysiol. 14 2003:940-948.
CrossRef | PubMed
Sweeney  M.O., Wathen  M.S., Volosin  K.; Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 111 2005:2898-2905.
CrossRef | PubMed
Higgins  S.L., Lee  R.S., Kramer  R.L.; Stability: an ICD detection criterion for discriminating atrial fibrillation from ventricular tachycardia. J Cardiovasc Electrophysiol. 6 1995:1081-1088.
CrossRef | PubMed
Kuhlkamp  V., Dornberger  V., Mewis  C.; Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol. 10 1999:905-915.
CrossRef | PubMed
Moss  A.J., Greenberg  H., Case  R.B.;Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 110 2004:3760-3765.
CrossRef | PubMed
Swerdlow  C.D., Cannom  D.S.; Supraventricular tachycardia–ventricular tachycardia discrimination algorithms in implantable cardioverter defibrillators: state-of-the-art review. J Cardiovasc Electrophysiol. 12 2001:606-612.
CrossRef | PubMed
Wilkoff  B.L., Hess  M., Young  J.; Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol. 15 2004:1002-1009.
CrossRef | PubMed
Theuns  D., Klootwijk  A., Simoons  M.; Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. Am J Cardiol. 95 2005:271-274.
CrossRef | PubMed
Alter  P., Waldhans  S., Plachta  E.; Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 28 2005:926-932.
CrossRef | PubMed
Goldenberg  I., Moss  A.J., McNitt  S.; Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 17 2006:931-936.
CrossRef | PubMed
Johnson  N.J., Marchlinski  F.E.; Arrhythmias induced by device antitachycardia therapy due to diagnostic nonspecificity. J Am Coll Cardiol. 18 1991:1418-1425.
CrossRef | PubMed
Florin  T.J., Weiss  D.N., Peters  R.W.; Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. Am J Cardiol. 80 1997:960-962.
CrossRef | PubMed
Swerdlow  C.D., Ahern  T., Chen  P.S.; Underdetection of ventricular tachycardia by algorithm to enhance specificity in a tiered therapy cardioverter defibrillator. J Am Coll Cardiol. 24 1994:416-424.
CrossRef | PubMed
Glikson  M., Swerdlow  C.D., Gurevitz  O.T.; Optimal combination of discriminators for differentiating ventricular from supraventricular tachycardia by dual-chamber defibrillators. J Cardiovasc Electrophysiol. 16 2005:732-739.
CrossRef | PubMed
Bansch  D., Steffgen  F., Gronefeld  G.; The 1+1 Trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation. 110 2004:1022-1029.
CrossRef | PubMed
LeFranc  P., Kus  T., Vinet  A.; Underdetection of ventricular tachycardia using a 40 ms stability criterion: effect of antiarrhythmic therapy. Pacing Clin Electrophysiol. 20 1997:2882-2892.
CrossRef | PubMed
Deisenhofer  I., Kolb  C., Ndrepepa  G.; Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies?. A randomized, prospective study. [see comment] J Cardiovasc Electrophysiol. 12 2001:134-142.
CrossRef | PubMed
Hintringer  F., Schwarzacher  S., Eibl  G.; Inappropriate detection of supraventricular arrhythmias by implantable dual chamber defibrillators: a comparison of four different algorithms. Pacing Clin Electrophysiol. 24 2001:835-841.
CrossRef | PubMed
Friedman  P.A., McClelland  R.L., Bamlet  W.R.; Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. Circulation. 113 2006:2871-2879.
CrossRef | PubMed
Sweeney  M.O.; Overcoming the defects of a virtue: dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. Circulation. 113 2006:2862-2864.
CrossRef | PubMed
Wilkoff  B.L., Kuhlkamp  V., Volosin  K.; Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection: results and technical considerations. Circulation. 103 2001:381-386.
CrossRef | PubMed
Ridley  D.P., Gula  L.J., Krahn  A.D.; Atrial response to ventricular antitachycardia pacing discriminates mechanism of 1:1 atrioventricular tachycardia. J Cardiovasc Electrophysiol. 16 2005:601-605.
CrossRef | PubMed
Berger  R.D., Lerew  D.R., Smith  J.M.; The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 17 2006:749-753.
CrossRef | PubMed
Saba  S., Gorodeski  R., Yang  S.; Use of correlation waveform analysis in discrimination between anterograde and retrograde atrial electrograms during ventricular tachycardia. [see comment] J Cardiovasc Electrophysiol. 12 2001:145-149.
CrossRef | PubMed
Brodine  W.N., Tung  R.T., Lee  J.K.; Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 96 2005:691-695.
CrossRef | PubMed
Pacifico  A., Hohnloser  S.H., Williams  J.H.; Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l–Sotalol Implantable Cardioverter-Defibrillator Study Group. [comment] N Engl J Med. 340 1999:1855-1862.
CrossRef | PubMed
Connolly  S.J., Dorian  P., Roberts  R.S.; Optimal pharmacological therapy in cardioverter defibrillator patients I. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. [see comment] JAMA. 295 2006:165-171.
CrossRef | PubMed
Res  J., Theuns  D., Jordaens  L.; The role of remote monitoring in the reduction of inappropriate implantable cardioverter defibrillator therapies. Clin Res Cardiol. 95 2006:iii17-iii21.
CrossRef | PubMed
Schoenfeld  M.H., Compton  S.J., Mead  R.H.; Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. [see comment] Pacing Clin Electrophysiol. 27 2004:757-763.
CrossRef | PubMed
Lee  K.L., Lau  C.P.; Inappropriate defibrillator therapies: are dual chamber devices providing a remedy?. [comment] J Cardiovasc Electrophysiol. 12 2001:143-144.
CrossRef | PubMed
Hallett  N., Monahan  K., Casavant  D.; Inadequacy of qualitative implantable cardioverter defibrillator electrogram analysis to distinguish supraventricular from ventricular tachycardia due to electrogram changes during normally conducted complexes. Pacing Clin Electrophysiol. 20 1997:1723-1726.
CrossRef | PubMed
Piotrowicz  K., Noyes  K., Lyness  J.M.; Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J. 28 2007:601-607.
CrossRef | PubMed

Figures

Grahic Jump Location
Figure 1

Survival Free of Inappropriate Shock/Therapy

(A) The cumulative proportion of patients who experienced a first inappropriate shock (due to any mechanism) is plotted versus time. (B) The cumulative proportion of patients who experienced a first inappropriate therapy, antitachycardia pacing (ATP) or shock (due to any mechanism) is plotted versus time. The number of patients at risk at a given time point of follow-up is indicated below the x axis. The proportion of the population experiencing the event in question is given in parentheses at the 1-, 2-, and 3-year time points.

Grahic Jump Location
Figure 2

Time-Dependent Occurrence of Inappropriate Shock by Type

The cumulative proportion of patients experiencing a first inappropriate (Inapp.) shock due to the 3 subcategories of inappropriate shock is plotted with respect to time. The number of patients at risk at a given time point of follow-up is indicated below the x axis. The proportion of the population experiencing the event in question is given in parentheses at the 1-, 2-, and 3-year time points. AF = atrial fibrillation or atrial flutter; ICD = implantable cardioverter-defibrillator; SVT = supraventricular tachycardia.

Grahic Jump Location
Figure 3

Ventricular Rate Precipitating Inappropriate Shock

The heart rate at the time of the ICD detection resulting in a patient’s first inappropriate shock is shown in the bar graph in groups of 10 beats/min. Atrial fibrillation episodes are shown with cross-hatched bars, and SVT episodes are shown with solid bars. Inappropriate shocks caused by abnormal sensing are excluded because the device has by definition misconstrued the actual ventricular rate (typically normal in these cases). The events relate to shocks, not patients, in this figure. Abbreviations as in (Figure 2).

Tables

Table Grahic Jump Location
Table 1Patients Experiencing Inappropriate ICD Shocks
Table Grahic Jump Location
Table 2Rhythm Responsible for ICD Shock Episodes
Table Grahic Jump Location
Table 3Clinical Characteristics of Patients With Versus Without Inappropriate ICD Shock
Table Footer NoteA dual-chamber or single-chamber device was implanted at the investigator’s discretion.
Table Footer NoteA blinded committee adjudicated deaths using a modified Hinkle-Thaler classification.
Table Grahic Jump Location
Table 4Predictors of Inappropriate Shock by Cox Proportional Hazards Regression Analysis
Table Grahic Jump Location
Table 5ICD Programming in Patients With and Without Inappropriate ICD Shocks
Table Footer Notep values from stratified Mann-Whitney rank test and difference-between-proportions test, for continuous and dichotomized measures, respectively. Values were consistent with corresponding ones from nonstratified tests.
Table Footer NoteSelected randomly from among the 635 patients without inappropriate shocks, matching on history of atrial fibrillation, smoking, and appropriate shock; see text for details.
Table Grahic Jump Location
Table 6Predictors of All-Cause Mortality by Cox Proportional Hazards Regression Analysis

Interactive Graphics

Video

References

The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias. N Engl J Med. 337 1997:1576-1583.
CrossRef | PubMed
Buxton  A., Lee  K., Fisher  J.; A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 341 1999:1882-1890.
CrossRef | PubMed
Moss  A.J., Zareba  W., Hall  W.J.; Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 348 2002:877-883.
CrossRef
Bardy  G.H., Lee  K.L., Mark  D.B.;Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 352 2005:225-237.
CrossRef | PubMed
Kadish  A., Dyer  A., Daubert  J.P.;Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 350 2004:2151-2158.
CrossRef | PubMed
Grimm  W., Flores  B.T., Marchlinski  F.E.; Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation. 87 1993:1880-1888.
CrossRef | PubMed
Rosenqvist  M., Beyer  T., Block  M.; Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. Circulation. 98 1998:663-670.
CrossRef | PubMed
Kron  J.; Clinical significance of device-related complications in clinical trials and implications for future trials: insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Card Electrophysiol Rev Cardiovasc Med. 7 2003:473-478.
CrossRef
Swerdlow  C.D., Friedman  P.A.; Advanced ICD troubleshooting: part I. Pacing Clin Electrophysiol. 28 2005:1322-1346.
CrossRef | PubMed
Gold  M.R., Peters  R.W., Johnson  J.W.; Complications associated with pectoral implantation of cardioverter defibrillators. Pacing Clin Electrophysiol. 20 1997:208-211.
CrossRef | PubMed
Epstein  A.E., Kay  G.N., Plumb  V.J.; Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation. 98 1998:1517-1524.
CrossRef | PubMed
Avitall  B., Port  S., Gal  R.; Automatic implantable cardioverter/defibrillator discharges and acute myocardial injury. Circulation. 81 1990:1482-1487.
CrossRef | PubMed
Finkelmeier  B., Kenwood  N., Summers  C.; Psychological ramifications of surviving sudden cardiac death. Crit Care Q. 1 1984:71-79.
Luderitz  B., Jung  W., Deister  A.; Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol. 16 1993:1815-1821.
CrossRef | PubMed
Schron  E.B., Exner  D.V., Yao  Q.; Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial. Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 105 2002:589-594.
CrossRef | PubMed
Prudente  L.A.; Phantom shock in a patient with an implantable cardioverter defibrillator: case report. Am J Crit Care. 12 2003:144-146.
PubMed
Jones  G., Johnson  G., Troutman  C.; Incidence of atrial fibrillation following ventricular defibrillation with transvenous lead systems in man. J Cardiovasc Electrophysiol. 3 1992:411-417.
CrossRef
Vollmann  D., Luthje  L., Vonhof  S.; Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2 2005:307-309.
CrossRef | PubMed
Klein  R.C., Raitt  M.H., Wilkoff  B.L.; Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Cardiovasc Electrophysiol. 14 2003:940-948.
CrossRef | PubMed
Sweeney  M.O., Wathen  M.S., Volosin  K.; Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 111 2005:2898-2905.
CrossRef | PubMed
Higgins  S.L., Lee  R.S., Kramer  R.L.; Stability: an ICD detection criterion for discriminating atrial fibrillation from ventricular tachycardia. J Cardiovasc Electrophysiol. 6 1995:1081-1088.
CrossRef | PubMed
Kuhlkamp  V., Dornberger  V., Mewis  C.; Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol. 10 1999:905-915.
CrossRef | PubMed
Moss  A.J., Greenberg  H., Case  R.B.;Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 110 2004:3760-3765.
CrossRef | PubMed
Swerdlow  C.D., Cannom  D.S.; Supraventricular tachycardia–ventricular tachycardia discrimination algorithms in implantable cardioverter defibrillators: state-of-the-art review. J Cardiovasc Electrophysiol. 12 2001:606-612.
CrossRef | PubMed
Wilkoff  B.L., Hess  M., Young  J.; Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol. 15 2004:1002-1009.
CrossRef | PubMed
Theuns  D., Klootwijk  A., Simoons  M.; Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. Am J Cardiol. 95 2005:271-274.
CrossRef | PubMed
Alter  P., Waldhans  S., Plachta  E.; Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 28 2005:926-932.
CrossRef | PubMed
Goldenberg  I., Moss  A.J., McNitt  S.; Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 17 2006:931-936.
CrossRef | PubMed
Johnson  N.J., Marchlinski  F.E.; Arrhythmias induced by device antitachycardia therapy due to diagnostic nonspecificity. J Am Coll Cardiol. 18 1991:1418-1425.
CrossRef | PubMed
Florin  T.J., Weiss  D.N., Peters  R.W.; Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. Am J Cardiol. 80 1997:960-962.
CrossRef | PubMed
Swerdlow  C.D., Ahern  T., Chen  P.S.; Underdetection of ventricular tachycardia by algorithm to enhance specificity in a tiered therapy cardioverter defibrillator. J Am Coll Cardiol. 24 1994:416-424.
CrossRef | PubMed
Glikson  M., Swerdlow  C.D., Gurevitz  O.T.; Optimal combination of discriminators for differentiating ventricular from supraventricular tachycardia by dual-chamber defibrillators. J Cardiovasc Electrophysiol. 16 2005:732-739.
CrossRef | PubMed
Bansch  D., Steffgen  F., Gronefeld  G.; The 1+1 Trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation. 110 2004:1022-1029.
CrossRef | PubMed
LeFranc  P., Kus  T., Vinet  A.; Underdetection of ventricular tachycardia using a 40 ms stability criterion: effect of antiarrhythmic therapy. Pacing Clin Electrophysiol. 20 1997:2882-2892.
CrossRef | PubMed
Deisenhofer  I., Kolb  C., Ndrepepa  G.; Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies?. A randomized, prospective study. [see comment] J Cardiovasc Electrophysiol. 12 2001:134-142.
CrossRef | PubMed
Hintringer  F., Schwarzacher  S., Eibl  G.; Inappropriate detection of supraventricular arrhythmias by implantable dual chamber defibrillators: a comparison of four different algorithms. Pacing Clin Electrophysiol. 24 2001:835-841.
CrossRef | PubMed
Friedman  P.A., McClelland  R.L., Bamlet  W.R.; Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. Circulation. 113 2006:2871-2879.
CrossRef | PubMed
Sweeney  M.O.; Overcoming the defects of a virtue: dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. Circulation. 113 2006:2862-2864.
CrossRef | PubMed
Wilkoff  B.L., Kuhlkamp  V., Volosin  K.; Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection: results and technical considerations. Circulation. 103 2001:381-386.
CrossRef | PubMed
Ridley  D.P., Gula  L.J., Krahn  A.D.; Atrial response to ventricular antitachycardia pacing discriminates mechanism of 1:1 atrioventricular tachycardia. J Cardiovasc Electrophysiol. 16 2005:601-605.
CrossRef | PubMed
Berger  R.D., Lerew  D.R., Smith  J.M.; The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 17 2006:749-753.
CrossRef | PubMed
Saba  S., Gorodeski  R., Yang  S.; Use of correlation waveform analysis in discrimination between anterograde and retrograde atrial electrograms during ventricular tachycardia. [see comment] J Cardiovasc Electrophysiol. 12 2001:145-149.
CrossRef | PubMed
Brodine  W.N., Tung  R.T., Lee  J.K.; Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 96 2005:691-695.
CrossRef | PubMed
Pacifico  A., Hohnloser  S.H., Williams  J.H.; Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l–Sotalol Implantable Cardioverter-Defibrillator Study Group. [comment] N Engl J Med. 340 1999:1855-1862.
CrossRef | PubMed
Connolly  S.J., Dorian  P., Roberts  R.S.; Optimal pharmacological therapy in cardioverter defibrillator patients I. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. [see comment] JAMA. 295 2006:165-171.
CrossRef | PubMed
Res  J., Theuns  D., Jordaens  L.; The role of remote monitoring in the reduction of inappropriate implantable cardioverter defibrillator therapies. Clin Res Cardiol. 95 2006:iii17-iii21.
CrossRef | PubMed
Schoenfeld  M.H., Compton  S.J., Mead  R.H.; Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. [see comment] Pacing Clin Electrophysiol. 27 2004:757-763.
CrossRef | PubMed
Lee  K.L., Lau  C.P.; Inappropriate defibrillator therapies: are dual chamber devices providing a remedy?. [comment] J Cardiovasc Electrophysiol. 12 2001:143-144.
CrossRef | PubMed
Hallett  N., Monahan  K., Casavant  D.; Inadequacy of qualitative implantable cardioverter defibrillator electrogram analysis to distinguish supraventricular from ventricular tachycardia due to electrogram changes during normally conducted complexes. Pacing Clin Electrophysiol. 20 1997:1723-1726.
CrossRef | PubMed
Piotrowicz  K., Noyes  K., Lyness  J.M.; Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J. 28 2007:601-607.
CrossRef | PubMed

Correspondence

Latest JACC CME

Continuing Medical Education through JACC is a convenient way to fulfill your CME requirements while learning important information about the latest advances in cardiovascular medicine.

April 2013- JACC CME Activity
Repeat Revascularization and Outcome

March 2013- JACC CME Activity
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction

Feb 2013- JACC CME Activity
Results from the BARI 2D Trial

Jan 2013- JACC CME Activity
Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Dec 2012- JACC CME Activity
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

Nov 2012- JACC CME Activity
A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials

Oct 2012- JACC CME Activity
Radiofrequency Ablation of Premature Ventricular Ectopy Improves the Efficacy of Cardiac Resynchronization Therapy in Nonresponders

Sept 2012- JACC CME Activity
Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease

Aug 2012- JACC CME Activity
Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

July 2012- JACC CME Activity
Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction

For previous CME quizzes, please follow this link to CardioSource Lifelong Learning and MOC.

 

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles